Teladoc Health (NYSE:TDOC) will release its earnings data after the market closes on Wednesday, October 30th. Analysts expect Teladoc Health to post earnings of ($0.40) per share for the quarter. Persons interested in registering for the company’s earnings conference call can do so using this link.
Teladoc Health (NYSE:TDOC) last released its quarterly earnings results on Wednesday, July 31st. The health services provider reported ($0.41) earnings per share for the quarter, missing the consensus estimate of ($0.40) by ($0.01). The firm had revenue of $130.30 million for the quarter, compared to analysts’ expectations of $129.54 million. Teladoc Health had a negative net margin of 21.85% and a negative return on equity of 10.64%. The business’s quarterly revenue was up 37.8% compared to the same quarter last year. During the same quarter in the prior year, the business earned ($0.40) EPS. On average, analysts expect Teladoc Health to post $-2 EPS for the current fiscal year and $-1 EPS for the next fiscal year.
NYSE TDOC opened at $68.15 on Wednesday. The stock has a market capitalization of $4.91 billion, a PE ratio of -47.33 and a beta of 1.37. The business has a 50 day simple moving average of $67.11 and a two-hundred day simple moving average of $62.85. The company has a debt-to-equity ratio of 0.43, a current ratio of 7.56 and a quick ratio of 7.56. Teladoc Health has a 1-year low of $42.08 and a 1-year high of $75.93.
Several research firms have weighed in on TDOC. JPMorgan Chase & Co. raised their price target on Teladoc Health from $82.00 to $83.00 and gave the company an “overweight” rating in a report on Thursday, September 19th. Oppenheimer set a $83.00 price target on Teladoc Health and gave the company a “buy” rating in a report on Friday, September 6th. Deutsche Bank began coverage on Teladoc Health in a report on Thursday, September 12th. They set a “buy” rating and a $76.00 price target for the company. Svb Leerink restated an “outperform” rating on shares of Teladoc Health in a report on Thursday, August 1st. Finally, SunTrust Banks raised their price target on Teladoc Health to $80.00 and gave the company a “positive” rating in a report on Tuesday, August 6th. Two research analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has assigned a strong buy rating to the company. The stock currently has a consensus rating of “Buy” and an average price target of $79.14.
In other news, insider Lewis Levy sold 675 shares of Teladoc Health stock in a transaction that occurred on Wednesday, September 4th. The stock was sold at an average price of $60.00, for a total value of $40,500.00. Following the completion of the transaction, the insider now owns 4,805 shares in the company, valued at approximately $288,300. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, SVP Andrew Turitz sold 9,158 shares of Teladoc Health stock in a transaction that occurred on Monday, September 9th. The stock was sold at an average price of $62.27, for a total value of $570,268.66. Following the completion of the transaction, the senior vice president now owns 6,827 shares of the company’s stock, valued at approximately $425,117.29. The disclosure for this sale can be found here. In the last quarter, insiders sold 14,558 shares of company stock valued at $937,219. Company insiders own 3.14% of the company’s stock.
About Teladoc Health
Teladoc Health, Inc provides telehealth services. It offers a portfolio of services and solutions covering 450 medical subspecialties, such as flu and upper respiratory infections, cancer, and congestive heart failure. The company provides its services through mobile devices, the Internet, video, and phone.
Featured Article: Understanding debt-to-equity ratio in fundamental analysis
Receive News & Ratings for Teladoc Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Teladoc Health and related companies with MarketBeat.com's FREE daily email newsletter.